Ed Ver detailed in the three previously published shall have 14 articles.12 PEEM frequencies using risk ratios and Fisher exact test 2-sided, due to the nature of how indicated.19 nachtr Adjusted analysis, made no formal hypothesis testing. All P values and evidence of statistical significance was included for exploratory purposes only. RESULTS of 2016 patients in the ITT population combined, completed studies in 1738. A total of 931 patients, were again U nebivolol and 110, the U placebo were re-classified as having hypertension stage II. Overall, treatment groups Were similar in terms of demographics and clinical baseline were significant differences in the proportions of black patients, patients with diabetes, and those found in au OUTSIDE the United States. Effects of nebivolol on blood pressure and heart rate at week 12 were the reduction of base-PAD and PAS clearly h Nebivololat ago with all recommended doses compared to placebo. DBP was significantly reduced with the other 2 doses as early as week 2 to week 12 nebivolol, with the exception of 1.25 mg / d dose at week 8, the reduction in SBP with significant nebivolol 1.25 mg / d 4 at week The overall results mean reductions in SBP and DBP were significantly h Ago with nebivolol in the recommended doses of 5 30/40 mg / day compared to placebo. The proportion of patients who achieved a response to treatment, significantly h Ago with nebivolol 2.5 40 mg / day compared to placebo. all recommended doses subtracted placebo h HIGHEST ratio trough sitting DBP Pemetrexed Alimta ratio was 0.9. This value was 1.3 with both the 1.25 and 2.5 mg / dose. Study reductions in personnel base to end, were significantly h Ago with the recommended dose of nebivolol compared to placebo. Doses of 2.5 30/40 mg / d were associated with a lot of st Rkere reductions in HR compared to placebo at week 2 and all subsequent visits.
The overall average reduction of HR was significantly gr It with the recommended dose compared to placebo, nebivolol. In the total population Lkerung of patients with black skin, reducing the DBP were significantly h Her at all doses, nebivolol compared to placebo, and the reduction of SBP were significantly h Forth in doses of 10 and 30/40 mg / day. Erm APPROPRIATIONS in HR and the proportions of patients who were significantly h reaction Forth with all recommended doses of nebivolol compared to placebo in the subpopulation of blacks. In this subgroup, placebo subtracted h HIGHEST ratio Ratio for sitting trough DBP at the recommended dose was 0.7 mg theException with 10 / d at doses of 1.25 and 2.5 mg / day these values were 1, 6 and 0.7, respectively. The general tolerance, differences in the H FREQUENCY of TEAEs in patients who again U nebivolol compared to those with re U placebo reached statistical significance, 806 nebivolol patients experienced at least one TEAE compared with 79 patients with re u placebo. 20 and 30/40 mg / d doses were associated with a significantly h Higher risk for any TEAE compared with placebo. The most hours Ufigsten reported were headache, nasopharyngitis and fatigue. The Pr Prevalence of fatigue was significantly gr It with nebivolol.